Oncotarget involves all pathways, cellular and molecules functions in aging and cancer, lymphocytes, neurons, atherosclerosis, microbes and cancer cells in an individual. It involves extensive research and applications of the results acquired.It is an international, journal that is peer reviewed which focuses on the pathological basis of cancers and potential patients for treatment and therapy protocols engaged to manage and control cancer patients. The journal focuses on therapeutic protocols and focuses on the impact of patient’s perspectives such as satisfaction, quality of life and adherence. This journal dives deep the existing and new therapies that improve the patient’s outcomes and overall the patients’ health care.
Oncotarget has free access and publishes it papers weekly and can be printed to the viewers on special demand. The journal’s main purpose is to make scientific results of diseases known and readily available for those in need. To maximize the impact of research through precise reviews, the journal allows exceptional discoveries to be widely viewed. To make clinical science and basic applications help fight diseases. To eliminate boundaries between specialties.Under the leadership of scientists Mikhail Blagosklonny and Andrei V. Gudkov, the journal helps researchers contribute to development in science. The journal’s main goal is to live a life without diseases. Oncotarget has led to the launch of sections beyond oncology.Gastric cancer is the third most common lead of death in women and men all over the world. The prognosis of this cancer is irreversible giving patients less than a year to live. This has led to research to know new therapeutic targets of gastric cancer patients.
Tyrosine kinase c-MET, a receptor, is encoded by a protein known as the MET Proto-oncogene. In gastric cancer, these activations of MET have contributed to gene amplification leading to regrowth of the body cells that cancer has eaten away.Our aim is to investigate the MET application in other genetically altered diseases and gastric cancer. The MET application was assessed by initial screen test of the patient followed by FISH analysis obtained from the surgery. The effects of the treatment are also measured to check on the changes that it makes for the patient.As a member of the receptor tyrosine kinase family, c-MET plays a big role in tumor survival, growth metastasis, and angiogenesis. Its overexpression in gene application occurs in a significant position of gastric cancers.